

Cep 1643
RECEIVED

MAY 20 1999

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


MATRIX CUSTOMER
SERVICE CENTER

Applicants: Hans Josef Stauss

Serial No.: 09/101,413

Filed: August 7, 1998

For: Immunotherapy Using Cytotoxic T Lymphocytes (CTL)



Art Unit: 1643

Examiner:

Assistant Commissioner for Patents
Washington, D.C. 20231

#7
Ross
6/22/99
CONT'D

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicant submits a Supplemental Information Disclosure Statement, including three (3) pages of Form PTO-1449 and a copy of each document cited therein.

This Supplemental Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(b) prior to a first Office Action on the merits. It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any additional fees to Deposit Account No. 01-2507

U.S. Patents

<u>Number</u>	<u>Issue Date</u>	<u>Patentee</u>	<u>Class/Subclass</u>
4,844,893	07-04-1989	Honsik, et al.	424/85.8
4,690,915	09-01-1987	Rosenberg	514/002

Publications

DAHL, et al., "Normal Self Proteins as Targets for Tumour Specific Cytotoxic Lymphocytes (CTL)," 9th International Congress of Immunology, San Francisco, CA, USA 607 (1995).

DAHL, et al., "A synthetic peptide derived from the tumor-associated protein mdm2 can stimulate autoreactive, high avidity cytotoxic T lymphocytes that recognize naturally processed protein," *J Immunol* 157(1):239-46 (1996).

HILL, et al., "Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised," *J Exp Med* 181(6):2221-8 (1995).

HSU, et al., "Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells," *Nat Med* 2(1):52-8 (1996).

INOUE, et al., "Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels," *Blood* 88(6):2267-78 (1996).

JEROME, et al., "Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA," *J Immunol* 151(3):1654-62 (1993).

KAWAKAMI, et al., "Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas," *J Immunol* 148(2):638-43 (1992).

KWAK, et al., "Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor," *Lancet* 345(8956):1016-20 (1995).

LU, et al., "Improved Synthesis of 4-Alkoxybenzyl Alcohol Resin," *J. Org. Chem.* 46: 3433-3436 (1981).

MELIEF, Prospects of T-cell immunotherapy for cancer by peptide vaccination," *Semin Hematol* 30(3 Suppl 3):32-3 (1993).

MENNSEN, et al., "Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias," *Leukemia* 9(6):1060-7 (1995).

MURPHY, et al., "Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen," *Prostate* 29(6):371-80 (1996).

PEOPLES, et al., "Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide," *Proc Natl Acad Sci U S A* 92(2):432-6 (1995).

PLEBANSKI, et al., "Induction of peptide-specific primary cytotoxic T lymphocyte responses from human peripheral blood," *Eur J Immunol* 25(6):1783-7 (1995).

U.S.S.N.: 09/101,413
Filed: August 7, 1998
SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

RODECK, et al., "Expression of the wt1 Wilms' tumor gene by normal and malignant human melanocytes," *Int J Cancer* 59(1):78-82 (1994).

SHIMAMOTO, et al., "The expression pattern of erythrocyte/megakaryocyte-related transcription factors GATA-1 and the stem cell leukemia gene correlates with hematopoietic differentiation and is associated with outcome of acute myeloid leukemia," *Blood* 86(8):3173-80 (1995).


TAMAKI, et al., "Increased expression of the Wilms tumor gene (WT1) at relapse in acute leukemia," *Blood* 88(11):4396-8 (1996).

VIEL, et al., "Molecular mechanisms possibly affecting WT1 function in human ovarian tumors," *Int J Cancer* 57(4):515-21 (1994).

Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicant invites the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicant is of the opinion that his claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,



Robert A. Hodges
Reg. No. 41,074

Dated: May 13, 1999

ARNALL GOLDEN & GREGORY, LLP
2800 One Atlantic Center
1201 West Peachtree Street
Atlanta, Georgia 30309-3450
(404) 873-8796
(404) 873-8797 (fax)

U.S.S.N.: 09/101,413
Filed: August 7, 1998
SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

Certificate of Mailing under 37 CFR §1.8(a)

I hereby certify that this Supplemental Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: May 14, 1999

Kristi Herring
Kristin Herring